Eli Lilly Announces $1.8 Billion Investment in Manufacturing for Weight Loss, Diabetes, and Alzheimer's Drugs

• Eli Lilly announced plans to invest $1.8 billion to increase manufacturing for its recently approved Alzheimer's drug and widely used weight loss and diabetes treatments, as well as other medications, in Ireland.
• The pharmaceutical company announced that it will invest $1 billion to expand its facility in Limerick, Ireland, to increase the production of specific active ingredients, including those utilized in its Alzheimer's treatment Kisunla.
• Eli Lilly's diabetes and weight loss drugs are being manufactured in a new $800 million facility expansion in Kinsale, Ireland, which began operations in 2023.

On Thursday, the company announced that it will invest $1.8 billion to increase manufacturing for its newly approved Alzheimer's drug and popular weight loss and diabetes treatments, as well as other medicines, in Ireland.

The pharmaceutical giant is investing $1 billion to expand its production capabilities in Limerick, Ireland, for certain active ingredients in drugs, including those used in its Alzheimer's treatment Kisunla, which was approved in the U.S. in July.

Eli Lilly announced an $800 million facility expansion in Kinsale, Ireland, which began manufacturing drugs in 2023 to meet demand for the company's diabetes and obesity treatments, according to a press release.

Since 2020, Eli Lilly has invested over $20 billion to increase production of its obesity drug Zepbound and diabetes injection Mounjaro, which has exceeded demand and resulted in a shortage.

"These investments will enhance the production of certain medicines, which will benefit millions of people with diabetes, obesity, and Alzheimer's disease in leading healthier lives," stated Edgardo Hernandez, Eli Lilly's president of manufacturing operations. "We will not stop there; these advanced facilities will also be capable of supporting our future pipeline molecules."

In the weight loss drug market, Eli Lilly's main competitor has also invested heavily in increasing the production of its own medications.